XSTOAMNI
Market cap1mUSD
Sep 27, Last price
0.01SEK
Name
Amniotics AB (publ)
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
72.50%
Rev. gr., 5y
%
Revenues
0k
Net income
-31m
L-37.51%
CFO
-29m
L-37.01%
Profile
Amniotics AB (publ) develops, manufactures, and sells stem cell therapies based on mesenchymal stem cells to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of inflammatory and fibrotic lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; and CutiStem for the treatment of dermatological indications. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 1,930 | 1,793 | 37,447 | |||
Unusual Expense (Income) | ||||||
NOPBT | (1,930) | (1,793) | (37,447) | |||
NOPBT Margin | ||||||
Operating Taxes | 1,353 | 4 | ||||
Tax Rate | ||||||
NOPAT | (1,930) | (3,146) | (37,451) | |||
Net income | (30,870) -37.51% | (49,399) -7.88% | (53,623) 72.98% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 34,789 | 60,963 | ||||
BB yield | -137.74% | -3.41% | ||||
| Debt | ||||||
Debt current | 2,580 | 15,067 | 732 | |||
Long-term debt | 15,067 | 732 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 22,711 | |||||
Net debt | (5,632) | 21,030 | (42,517) | |||
| Cash flow | ||||||
Cash from operating activities | (29,091) | (46,185) | (15,634) | |||
CAPEX | (2,666) | (3,027) | (1,144) | |||
Cash from investing activities | (2,666) | (3,027) | (1,144) | |||
Cash from financing activities | 30,865 | 14,335 | 60,248 | |||
FCF | (3,578) | (2,201) | (43,140) | |||
| Balance | ||||||
Cash | 8,212 | 9,104 | 43,981 | |||
Long term investments | ||||||
Excess cash | 8,212 | 9,104 | 43,981 | |||
Stockholders' equity | (84,544) | (59,309) | (11,263) | |||
Invested Capital | 109,274 | 75,859 | 61,419 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 2,806,363 | 164,838 | 164,838 | |||
Price | 0.01 -99.24% | 1.19 -89.09% | 10.86 | |||
Market cap | 25,257 -87.07% | 195,333 -89.09% | 1,790,139 | |||
EV | 19,625 | 216,363 | 1,747,622 | |||
EBITDA | 371 | (35,294) | ||||
EV/EBITDA | 52.90 | |||||
Interest | 1,797 | 1,389 | 4 | |||
Interest/NOPBT | ||||||